Updated Follow-up Analysis in the REP 401 Protocol: Treatment of HBeAg Negative Chronic HBV Infection with REP 2139 or REP 2165, Tenofovir Disoproxil Fumarate and Pegylated Interferon α-2a

被引：0

作者：

Bazinet, M. ^{[1
]}

Pantea, V. ^{[2
]}

Placinta, G. ^{[2
]}

Moscalu, I. ^{[3
]}

Cebotarescu, V. ^{[2
]}

Cojuhari, L. ^{[2
]}

Jimbei, P. ^{[4
]}

Iarovoi, L. ^{[2
]}

Smesnoi, V. ^{[4
]}

Musteata, T. ^{[4
]}

Jucov, A. ^{[3
]}

Krawczyk, A. ^{[5
]}

Vaillant, A. ^{[1
]}

机构：

[1] Replicor, Montreal, PQ, Canada

[2] State Univ Med & Pharm Nicolae Testemitanu, Fac Postgrad Educ, Dept Infect Dis, Kishinev, Moldova

[3] ARENSIA Exploratory Med, Republican Clin Hosp, Phase Unit 1, Dusseldorf, Germany

[4] Infect Clin Hosp Toma Ciorba, Kishinev, Moldova

[5] Univ Klinikum Essen, Inst Virol, Essen, Germany

来源：

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

O-018

引用

页码：14 / 14

页数：1

共 22 条